 Tumor immunotherapy based on specific tumor antigen has become the focus for breast cancer and research into cancer testes antigens is progressing . As an important member in the CTA NY ESO 1 plays a crucial role in the treatment and prognosis of breast cancer . In this study we aimed to improve the binding ability to MHC by designing and synthesizing stable NY ESO 1 derived peptides based on NetMHC 4.0 webserver

@highlight Strong affinity to HLA A2.
@highlight Nearly non existent cytotoxicity and tissue toxicity
@highlight and
@highlight Significant specific kinging effect against HLA A2 NY ESO 1 double positive breast cancer both
@highlight and
